Shannon Morris, the Chief Medical Officer of $ERAS, sold 20,000 shares of the company on 03-04-2026 for an estimated $300,760. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares of this class of stock. Following this trade, they now own 0 shares of this class of $ERAS stock.
$ERAS Insider Trading Activity
$ERAS insiders have traded $ERAS stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ERAS stock by insiders over the last 6 months:
- EBUN GARNER (General Counsel & Corp. Sec.) sold 120,000 shares for an estimated $670,812
- SHANNON MORRIS (Chief Medical Officer) sold 20,000 shares for an estimated $300,760
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ERAS Hedge Fund Activity
We have seen 73 institutional investors add shares of $ERAS stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 15,445,081 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $57,455,701
- LOGOS GLOBAL MANAGEMENT LP removed 2,150,000 shares (-14.2%) from their portfolio in Q4 2025, for an estimated $7,998,000
- STATE STREET CORP added 2,145,386 shares (+53.2%) to their portfolio in Q4 2025, for an estimated $7,980,835
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,490,967 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,546,397
- SIO CAPITAL MANAGEMENT, LLC removed 1,369,748 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,095,462
- PFM HEALTH SCIENCES, LP removed 1,072,224 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,337,448
- ROCK SPRINGS CAPITAL MANAGEMENT LP added 951,710 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,540,361
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ERAS Analyst Ratings
Wall Street analysts have issued reports on $ERAS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/14/2025
- Stifel issued a "Buy" rating on 10/16/2025
To track analyst ratings and price targets for $ERAS, check out Quiver Quantitative's $ERAS forecast page.
$ERAS Price Targets
Multiple analysts have issued price targets for $ERAS recently. We have seen 6 analysts offer price targets for $ERAS in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Kaveri Pohlman from Clear Street set a target price of $20.0 on 03/06/2026
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $15.0 on 01/26/2026
- Kelsey Goodwin from Piper Sandler set a target price of $11.0 on 01/16/2026
- Graig Suvannavejh from Mizuho set a target price of $5.0 on 12/09/2025
- Michael Schmitz from Guggenheim set a target price of $5.0 on 11/14/2025
- Laura Prendergast from Stifel set a target price of $4.0 on 10/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
